Abstract
Natural killer (NK) cells are known to play a role in mediating innate immunity and have been implicated in mediating anti-tumor responses via antibody-dependent cell-mediated cytotoxicity (ADCC) based on the reactivity of CD16 with the Fc region of human IgG1 antibodies. The NK-92 cell line, devoid of CD16 and derived from a lymphoma patient, has been well characterized. The adoptive transfer of irradiated NK-92 cells demonstrated safety and showed preliminary evidence of clinical benefit for cancer patients. The molecules 41BB and CD3 are commonly used as stimulators in the CAR structure, and their expression in NK cells can promote the activation of NK cells, leading to the enhanced perforin- and granzyme-mediated lysis of tumor cells. This study showed that genetically modified NK-92 cells combined with antibody-mediated ADCC using rituximab and trastuzumab monoclonal antibodies lysed tumor cells more efficient than the NK-92 cell lines. It also showed that the anti-tumor activity of chimeric stimulator molecules of the CAR-modified CD16 receptor was stronger than that of CD16 (allotype V158). These studies provide a rationale for the use of genetically modified NK-92 cells in combination with IgG1 anti-tumor monoclonal antibodies. We also provide a rationale for the chimeric modified CD16 receptor that can improve the anti-tumor effect of NK92 cells via ADCC.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
All the cell lines, raw experimental data, data on statistical analysis and/or detailed explanations regarding Materials and methods are available from the corresponding author on reasonable request.
References
Barrett DM, Teachey DT, Grupp SA (2014) Toxicity management for patients receiving novel T-cell engaging therapies. Curr Opin Pediatr 26:43–49. https://doi.org/10.1097/mop.0000000000000043
Bibeau F, Lopez-Crapez E, Di Fiore F et al (2009) Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 27:1122–1129. https://doi.org/10.1200/JCO.2008.18.0463
Bradley M, Zeytun A, Rafi-Janajreh A et al (1998) Role of spontaneous and interleukin-2-induced natural killer cell activity in the cytotoxicity and rejection of Fas+ and Fas- tumor cells. Blood 92:4248–4255
Brown TL, Tucci J, Dyson ZA et al (2017) Dynamic interactions between prophages induce lysis in Propionibacterium acnes. Res Microbiol 168:103–112. https://doi.org/10.1016/j.resmic.2016.09.004
Campbell KS, Hasegawa J (2013) Natural killer cell biology: an update and future directions. J Allergy Clin Immunol 132:536–544. https://doi.org/10.1016/j.jaci.2013.07.006
Carson WE, Parihar R, Lindemann MJ et al (2001) Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells. Eur J Immunol 31:3016–3025
Cartron G, Dacheux L, Salles G et al (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99:754–758
Chen Y, You F, Jiang L et al (2017) Gene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody. Oncotarget 8:37128–37139. https://doi.org/10.18632/oncotarget.16201
Clemenceau B, Valsesia-Wittmann S, Jallas AC et al (2015) In vitro and in vivo comparison of lymphocytes transduced with a human CD16 or with a chimeric antigen receptor reveals potential off-target interactions due to the IgG2 CH2-CH3 CAR-spacer. J Immunol Res. https://doi.org/10.1155/2015/482089
Fabian KP, Padget MR, Donahue RN et al (2020) PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations. J Immunother Cancer. https://doi.org/10.1136/jitc-2019-000450
Fernandez-Messina L, Reyburn HT, Vales-Gomez M (2012) Human NKG2D-ligands: cell biology strategies to ensure immune recognition. Front Immunol 3:299. https://doi.org/10.3389/fimmu.2012.00299
Gladow M, Uckert W, Blankenstein T (2004) Dual T cell receptor T cells with two defined specificities mediate tumor suppression via both receptors. Eur J Immunol 34:1882–1891. https://doi.org/10.1002/eji.200425041
Gras Navarro A, Bjorklund AT, Chekenya M (2015) Therapeutic potential and challenges of natural killer cells in treatment of solid tumors. Front Immunol 6:202. https://doi.org/10.3389/fimmu.2015.00202
Jochems C, Hodge JW, Fantini M et al (2016) An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele. Oncotarget 7:86359–86373. https://doi.org/10.18632/oncotarget.13411
Klingemann H, Boissel L, Toneguzzo F (2016) Natural killer cells for immunotherapy: advantages of the NK-92 cell line over blood NK cells. Front Immunol 7:91. https://doi.org/10.3389/fimmu.2016.00091
Koene HR, Kleijer M, Algra J et al (1997) Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood 90:1109–1114
Kruschinski A, Moosmann A, Poschke I et al (2008) Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas. Proc Natl Acad Sci USA 105:17481–17486. https://doi.org/10.1073/pnas.0804788105
Montagner IM, Penna A, Fracasso G et al (2020) Anti-PSMA CAR-engineered NK-92 cells: an off-the-shelf cell therapy for prostate cancer. Cells. https://doi.org/10.3390/cells9061382
Paust S, Senman B, von Andrian UH (2010) Adaptive immune responses mediated by natural killer cells. Immunol Rev 235:286–296. https://doi.org/10.1111/j.0105-2896.2010.00906.x
Qin L, Lai YX, Zhao RC et al (2017) Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells. J Hematol Oncol. https://doi.org/10.1186/s13045-017-0437-8
Scott MP, Neese STT et al (2001) Changes in biosynthesis and degradation of juvenile hormone during breeding by burying beetles: a reproductive or social role? J Insect Physiol 47:295–302
Tam YK, Maki G, Miyagawa B et al (1999) Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy. Hum Gene Therapy 10:1359–1373. https://doi.org/10.1089/10430349950018030
Tassev DV, Cheng M, Cheung NKV (2012) Retargeting NK92 cells using an HLA-A2-restricted, EBNA3C-specific chimeric antigen receptor. Cancer Gene Ther 19:84–100. https://doi.org/10.1038/cgt.2011.66
Uchiyama S, Suzuki Y, Otake K et al (2010) Development of novel humanized anti-CD20 antibodies based on affinity constant and epitope. Cancer Sci 101:201–209. https://doi.org/10.1111/j.1349-7006.2009.01392.x
Vanherberghen B, Olofsson PE, Forslund E et al (2013) Classification of human natural killer cells based on migration behavior and cytotoxic response. Blood 121:1326–1334. https://doi.org/10.1182/blood-2012-06-439851
Weiner LM, Dhodapkar MV, Ferrone S (2009) Monoclonal antibodies for cancer immunotherapy. Lancet 373:1033–1040. https://doi.org/10.1016/S0140-6736(09)60251-8
Williams BA, Wang X-H, Leyton JV et al (2018) CD16 (+)NK-92 and anti-CD123 monoclonal antibody prolongs survival in primary human acute myeloid leukemia xenografted mice. Haematologica 103:1720–1729. https://doi.org/10.3324/haematol.2017.187385
Yang F, Shao Y, Yang F et al (2013) Valproic acid upregulates NKG2D ligand expression and enhances susceptibility of human renal carcinoma cells to NK cell-mediated cytotoxicity. Arch Med Sci 9:323–331. https://doi.org/10.5114/aoms.2013.34413
Yokoyama WM, Kim S (2006) Licensing of natural killer cells by self-major histocompatibility complex class I. Immunol Rev 214:143–154. https://doi.org/10.1111/j.1600-065X.2006.00458.x
Acknowledgements
This work was supported by a grant from the Institute of Biomedicine & National Engineering Research Center of Genetic Medicine, China.
Author information
Authors and Affiliations
Contributions
ZH and ZZl have contributed equally to the research. CW designed and provided the T-CD19-CAR. LGm, ZH and LSy analyzed the data. LGm, ZH, and LG wrote the paper.
Corresponding author
Ethics declarations
Conflict of interest
All authors have no conflicts of interest to declare.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the Supplementary Information.
Rights and permissions
About this article
Cite this article
Zhao, H., Zhou, Z., Li, G. et al. An NK cell line (NK92-41BB) expressing high levels of granzyme is engineered to express the high affinity chimeric genes CD16/CAR. Cytotechnology 73, 539–553 (2021). https://doi.org/10.1007/s10616-021-00476-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10616-021-00476-1